Talk about a blow to revenue! Shame how sick people don't have infinite money eh?

On Monday, a Delaware court denied the Swiss pharma giant's attempt for a preliminary injunction to block MSN Pharmaceuticals from launching their generic version on the U.S. market. 2024 guidance doesn't currently account for any generic releases of its best-selling drug Entresto in the U.S., the analysts say. "Should a generic Entresto get to the U.S. market, it would put about 1.5 billion U.S. dollars of Entresto at risk in 2H and another roughly 2 billion dollars next year, before we expect generic erosion following loss of exclusivity per mid-year 2025,"